Vimarsana
Biggest News Aggregation in the World

3sbio Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 3sbio Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 3sbio Inc Today - Breaking & Trending Today

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates - Vimarsana News

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

SUZHOU, China, March 27, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research,

Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances - Vimarsana News

Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances

/PRNewswire/ -- The "Biosimilar Monoclonal Antibodies Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The expansion of the...

3SBio Inc. (OTCMKTS:TRSBF) Sees Significant Growth in Short Interest - Vimarsana News

3SBio Inc. (OTCMKTS:TRSBF) Sees Significant Growth in Short Interest

3SBio Inc. (OTCMKTS:TRSBF – Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 574,000 shares, a growth of 57,300.0% from the December 15th total of 1,000 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is […]

Source: wkrb13.com
Global Immunology Market Soars with Projected $56.07 - Vimarsana News

Global Immunology Market Soars with Projected $56.07

Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The

CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China - Vimarsana News

CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China

SUZHOU, China, Nov. 1, 2023 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research,